Global Radiodermatitis Market: Research Analyst’s Findings
Strong and expanding prevalence of cancer is undeniable, but the failure of humanity to find an adequate therapy for the chronic disease ‘without side effects’ is another irrefutable reality. For now, cumulative daily doses of radiation therapy are used for cancer treatment, which causes a side-effect called radiodermatitis. Radiodermatitis significantly affects the patient’s quality of life by enticing debilitating pain and discomfort and can potentially hinder further treatment regimes. Thankfully, topical agents and dressings have been formulated that can efficiently negotiate with the repercussions of chemotherapy, and the market for radiodermatitis is flourishing. According to the calculations of this business intelligence report, the demand in the global radiodermatitis market will increment at a CAGR of 3.93% during the forecast period of 2017 to 2024. Revenue-wise, the radiodermatitis market is estimated to be worth US$421.5 million by the end of 2024, swelling up from its evaluated worth of US$321.9 million as of 2017.
According to the latest estimations by the American Cancer Society, there will be 21.7 million cases of cancer across the world by 2030. Owing to increased disposable income of urban populations and improving healthcare infrastructure in several emerging economies – substantially stronger pool of patients are expected to go through cancer treatment, which in turn will augment the demand in the radiodermatitis market. Industry-academia and industry-institute partnerships, innovations in product offering, and strengthening of distribution network by major manufacturers are some of the other factors foreseen to drive the radiodermatitis market. On the other hand, advent of equipment of radiation therapies such as intensity-modulated radiation therapy (IMRT) and proton therapy that impart fewer side effects is the prominent restraint over this market.
Hydrophilic Creams Market’s Key Product Sub-Segment
On the basis of product type, this report segments the radiodermatitis market into topical, dressings, and oral medication. The topical segment, which has been further sub-segmented into hydrophilic creams, corticosteroids, and others such as antibiotics, constituted for the most prominent chunk of demand in 2017, generating a revenue of US$225.8 million. Over the course of the forecast period of 2017 to 2024, the demand for topical segment is projected to multiply at an above-average CAGR of 4.2%. Topical steroids have shown the ability to inhibit the upregulation of cytokines in response to radiation and their demand is proliferating. The strong demand for hydrophilic creams, which is estimated to a demand worth of US$233.2 million by 2024, is a reflection of its effectiveness in preventive care in initial stages of radiation dermatitis.
In comparison to hydrophilic creams and corticosteroids, the antibiotics sub-segment is showing slower growth rate due to improvement in treatment regime during the forecast period, necessitating less dependence on antibiotics. Moreover, several radiation dermatitis specific creams such as Radiation Rescue and StrataXRT are antibacterial in nature. Hence, preference for combination topical agents is likely to restrain the topical antibiotics segment.
Radiodermatitis Market Segmentations
The oral medication segment has been bifurcated into corticosteroids and others such as oral analgesics and antibiotics, whereas the dressings segment has been classified into hydrocolloid, hydrogel, honey impregnated gauze, no sting barrier film, silicone coated dressing, and others such as silver leaf dressing and GM-CSF gauze. For each of the segment, the report includes figurative analysis on how the demand has evolved in the recent past and how it will shape in the near future. This report also gauges the potential of demand that is getting generated by the different distribution channels of online stores, retail pharmacies, and hospital pharmacy. This business intelligence report also contains a chapter on pipeline drugs, including a list of discontinued trials and open studies.
Vastly Populated Asia Pacific Most Lucrative Region
Geographically, Asia Pacific and Europe are the two regions with maximum potential, according to the analyst of this report. The Asia Pacific region has a significant pool of patients suffering from cancer as well as taking radiation therapy. Moreover, the basic preventive skincare practices such as washing skin with gentle soap and wearing loose clothing tend to be overlooked by the population in emerging countries. This further increases the need for radiation dermatitis care products. By the end of 2024, the Asia Pacific radiodermatitis market is estimated to be worth US$194.0 million, generating 46% of the total demand. The Europe radiodermatitis market is poised to attain a valuation of US$110.0 million.
Smith & Nephew PLC, 3M Healthcare, Acelity, Molnlycke Health Care, and Convatec, Inc. are a few key companies in the global radiodermatitis market.
Global Radiodermatitis Market: Overview
Radiodermatitis, also known as radiation dermatitis, is a peculiar symptom caused as a result of radiation therapy pertaining to the treatment of cancerous as well as noncancerous conditions, and has significant negative impact on a patient’s physical functionalities and quality of life. It has been estimated that in developed countries such as the U.S., Canada, Australia, the U.K, France, and Germany, nearly half of the patients who receive treatment for cancer was also subjected to radiation therapy during the illness, and about all of them experience some degree of skin reaction. As the cases of cancer escalates across the world, the demand in the global radiodermatitis is expected to increment at a considerable CAGR of 3.93% during the forecast period of 2017 to 2024.
This report, developed by a group of professional market research analysts, aspires to serve as a credible business tool for the stakeholders of this market. The report studies the prospects of various segments of the market, based on product, distribution channel, and geography, as well as profiles a number of leading players to understand the competitive landscape. Qualitative and quantitative assessment of all factors that may influence the demand for radiodermatitis has been provided in the report.
Global Radiodermatitis Market: Trends & Opportunities
According to the International Agency for Research on Cancer (IARC), there were 14.1 million new cases of cancer across the world, and the figure is estimated to reach up to 21.7 million by the end of 2030. This substantial patient volume is the primary driver of the global radiodermatitis market. In addition to that, increasing focus on product innovation as well as advancements in the existing products are also expected to favor the market in the near future. Growing number of private and public healthcare organizations, who are constantly trying to promote the awareness regarding radiodermatitis treatment and management, and rising number of clinical studies to evaluate the efficiency of radiodermatitis treatment are some of the other factors favoring the global radiodermatitis market.
Based on product, the global radiodermatitis market has been segmented into topical, oral medication, and dressings. While topical segment is sub-segmented into hydrophilic creams, corticosteroids, and others such as antibiotics, oral medical is further divided into corticosteroids and others such as antibiotics and oral analgesics, whereas dressing segment is further categorized into hydrogel, no sting barrier film, hydrocolloid, honey impregnated gauze, silicone coated dressing, and others such as silver leaf dressing and GM-CSF gauze. On the basis of dressing channel, the market has been bifurcated into hospital pharmacy, online store, and retail pharmacy store.
Global Radiodermatitis Market: Regional Outlook
Though the demand for radiodermatitis is growing in all regions across the globe, Asia Pacific currently serves the maximum demand, owing to higher percentage untapped patient-base. A number of emerging economies in the Asian region are situated in tropical region with humid weather conditions, in which the effect of radiation dermatitis is quite high. Extensive collaborations among the key players in order to increase their product portfolio and involvement of well-established pharmaceutical companies in this region on commercialization of their products are also expected to help them increment their shares in this region.
Companies mentioned in the research report
Smith & Nephew plc, 3M Healthcare, Acelity, Convatec, Inc., and Molnlycke Health Care are some of the key companies operating in this market.
Key Segments of the Global Radiodermatitis Market
Global Radiodermatitis Market, by Product
- Hydrophilic Creams
- Others (topical antibiotics)
- Oral Medication
- Other (oral analgesics, antibiotics, etc.)
- No Sting Barrier Film
- Honey Impregnated Gauze
- Silicone Coated Dressing
- Others (GM-CSF gauze, silver leaf dressing, etc.)
Global Radiodermatitis Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy Store
- Online Store
Global Radiodermatitis Market, by Geography
- North America
- Asia Pacific
- Rest of APAC
- Rest of Europe
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments